DDW’s Multimedia Editor Megan Thomas attended the Society for Neuroscience (SfN)’s Neuroscience 2024 in October 2024 in Chicago, US. Having published a general event roundup, here she unpacks the ‘Animals in Research’ panel: Lifesaving clinical advances stemming from animal research, which took place on Monday 7 October.

The panellists included Walter Koroshetz, Director of the National Institute of Neurological Disorders and Stroke (NINDS); Christian Lorson, Associate Vice Chancellor for Research and Strategic Initiatives at the University of Missouri as well as the Director of the Missouri-wide Spinal Cord Injusry/Disease Research Program (SCIDRP); Arjun Seth, a neuromuscular specialist and an Assistant Professor of Neurology at Northwestern University Feinberg School of Medicine; as well as Lauren Gibbs, the Site Activations Manager at Tempus AI, who was diagnosed with spinal muscular atrophy (SMA) Type III as a small child and whose participation in a clinical trial led to the first FDA approved treatment for SMA. The event, supported by The National Primate Research Centres, was moderated by Dr Katalin Gothard, a Professor in the departments of Physiology and Neuroscience at the University of Arizona.

A foundation built on animal models

Animal research has been instrumental in transforming Spinal Muscular Atrophy (SMA) from a devastating diagnosis to a manageable condition, making it a central topic of discussion at the ‘Animals in Research’ panel. Experts and advocates discussed what they consider to be the irreplaceable role animal models play in biomedical advancements. The panel appealed to the scientific audience to effectively communicate this importance to the public and policymakers to counter misinformation and foster understanding.

SMA, a genetic disorder affecting approximately one in 10,000 live births, stems from mutations in the SMN1 gene. Without sufficient survival motor neuron (SMN) protein, motor neurons deteriorate, leading to severe physical disabilities and, historically, early mortality in the most severe cases. The development of therapies for SMA relied heavily on animal models.

According to Lorson, the gold standard for therapeutic development is the Delta 7 mouse model. This mouse model, with a human SMN2 transgene, allowed researchers to replicate the disease’s progression and test therapies effectively, the panel noted. The model was pivotal in the development of three FDA-approved treatments: Spinraza, an antisense oligonucleotide; Risdiplam, a small molecule; and Zolgensma, a gene therapy.

From bench to bedside

The panel featured patient advocate Lauren Gibbs, who shared her journey with SMA type 3 and highlighted how animal research changed her life. She said: “After my second injection of the clinical trial drug, my dad and I noticed that not only was I able to shoot a basket, but I was able to shoot several baskets in a row and actually make it. It was a moment that I will never forget.” Gibbs’ story underscores how preclinical work in animal models translates into life-changing human treatments.

Her sister, Claire, who has SMA type 2, also benefited from these advancements. Gibbs added: “When Spinraza received FDA approval, it was a turning point for our family. Thanks to decades of research and the essential role of animal models, Claire finally had access to a treatment.”

Communicating the value of animal research

Panellists stressed the need to communicate the benefits of animal research in the face of public scepticism. Many people equate animal research with animal suffering, but the panellists believe the reality is far from this misconception. Scientists are required to adhere to strict ethical guidelines, ensuring humane treatment of animals while advancing medical knowledge. “Scientists are not mad people torturing animals. This image has to go,” said panel moderator Gothard.

Research organisations, including the National Primate Research Centers, supporters of this event at Neuroscience 2024, also support other initiatives to engage various audiences and clarify the necessity of animal studies. As part of this effort, institutions are fostering transparency and collaboration with patient groups. Kurt Leucht, from the European Animal Research Association, discussed a successful initiative in the Netherlands which involved bringing over 30 Parkinson’s patients into labs conducting both animal and in vitro research. This interaction reportedly demystified the process and empowered patients to advocate publicly for the scientific community.

The role of non-human primate research

The discussion also highlighted the growing demand for non-human primates in research, particularly for neurological and genetic therapies. Non-human primates bridge the gap between rodent models and human clinical trials due to their closer physiological similarities, but are a point of controversy internationally.

Critics argue that the use of non-human primates in research raises ethical concerns about animal welfare, leading to growing calls for alternatives. But Walter Koroshetz says: “The truth of the matter is that to move these things into people, you can’t go from mice to people, you have to go from mouse to non-human primate, because the circuits, particularly when you’re talking about things like depression or OCD, are not going to be as similar in the mouse as they would be in a non-human primate. For neuroscience, non-human primate research is critically important. It’s a stepping stone to the human and without that stepping stone, you’re going to drown when you try to make that leap.”

With that said, availability is limited, posing challenges to both public and private research sectors. NIH-supported research is facing shortages, and expanding access remains a financial and logistical hurdle.

Moving forward

As the panel concluded, speakers urged attendees to become advocates for animal research. They emphasised the importance of clear, empathetic communication to dispel myths and highlight the tangible benefits for patients. They urged attendees to help ensure that policymakers and the public understand that without animal research, breakthroughs, like those in SMA, wouldn’t exist.

The panel underscored the critical role animal models have played in advancing medical research, particularly in developing life-saving treatments like those for SMA. While animal research remains a point of contention, particularly regarding the use of non-human primates, the panel emphasised the ethical rigour and necessity of these studies in bridging the gap between basic science and human applications.

As scientific and patient communities continue to navigate this complex terrain, the discussion highlighted the importance of transparency, education, and advocacy to ensure that the value of animal research is clearly communicated and understood. Moving forward, it is crucial that researchers, patients, and policymakers collaborate to find common ground and uphold the principles that allow for continued progress in neurological research and beyond.

Megan ThomasMegan Thomas is Multimedia Editor on DDW. She has worked across a range of B2C and B2B publications, and was a digital editor at the British Medical Association. She has an undergraduate degree in Print Journalism, Film & Media and a master’s degree in Creative Writing.